Arrowhead Pharmaceuticals

Performance

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and delivering RNA interference (RNAi)–based therapies across multiple disease areas, including cardiometabolic and inflammatory pulmonary diseases. Its TRiM platform targets genes to silence disease-causing pathways, with programs addressing conditions such as severe hypertriglyceridemia, dyslipidemia, and various cardiovascular and lung diseases. The company operates globally with research and development activities and clinical trials in several countries, including the United States, Australia, Canada, and Europe.